Čeština
|
Dansk
|
Deutsch
|
English
|
Español
|
Français
|
Italiano
|
Nederlands
|
Norsk
|
Polski
|
Português
|
Pусский
|
Suomi
|
Svenska
|
US
EHDN2016
DISEASE
NETWORK
REGISTRY
PROJECTS
LOGIN
Wet Biomarkers
-
News
The Project
Sponsor
Executive Committee
Writing Committee Strategic ...
Scientific and Bioethics Advis...
Central Coordination
Language Coordination
Fellowship Programme
Constitution
Voting/Nomination
Members
Request
Locations
Working Groups
Events
EHDN 2016
EHDN 2014
EHDN 2012
Introduction
Announcement
Programme Fri
Programme Sat
Programme Sun
Additional Meetings
Important Dates
Registration
Travel & Accommodation
EHA Registration
EHA Programme
Reception Dinner
About Stockholm
Abstract Submission
Reimbursement
Documents
Handouts
Presentations
Posters
Pathogenic mechanisms
Animal models
Choreatic disorders - no...
Genetic modifiers
Wet Biomarkers
Imaging
Clin characteristics
Clin char-motor
Clin char-cognitive
Clin char - behaviour
Clin char-other
Clinical studies
Genetic testing
Clinical care
Experimental Rx
Clinical Rx
Non-scientific
Contacts
Feedback & Evaluation
EHDN 2010
EHDN 2008
EHDN 2007
EHDN 2006
EHDN 2005
EHDN 2004
Communication
Job Offers
date
description
size
author
document
03.08.26
Selisistat: potential pharmacodynamic readouts based on transcriptomics
32 kB
anonymous
f04-potential-pharmacodynamic-readouts
03.08.26
Mutant Huntingtin fragmentation in immune cells tracks Huntington’s Disease progression
32 kB
anonymous
f05-mutant-huntingtin-fragmentation
03.08.26
Whole blood SAGE digital gene expression profiling from Huntington's disease patients
32 kB
anonymous
f03-blood-sage-digital-gene-expression
03.08.26
Selisistat: Soluble htt protein levels as a potential pharmacodynamic readout
32 kB
anonymous
f02-soluble-htt-protein-levels
03.08.26
Establishment of novel assays for quantification of full-length wild-type and mutant Huntingtin by using the AlphaLISA technology
32 kB
anonymous
f01-establishment-novel-assays
03.08.26
A critical evaluation of inflammatory markers in Huntington’s Disease plasma
32 kB
anonymous
f06-critical-evaluation-inflammatory-m...
03.08.26
Cross-sectional and longitudinal associations between CRP and neuropsychiatric symptoms in HD
32 kB
anonymous
f07-crp-neuropsychiatric-symptoms
03.08.26
Abnormal regulation of macrophage-derived transforming growth factor – β 1 (TGF-β1) production in Huntington Disease
32 kB
anonymous
f12-abnormal-regulation-of-macrophage
03.08.26
8OHdG is not a biomarker for Huntington’s Disease; lessons for future biomarker studies
32 kB
anonymous
f14-8ohdg
03.08.26
Progredient deterioration of hepatic mitochondrial function in Huntington's Disease – measured by using the 13C-methionin breath test
32 kB
anonymous
f11-progredient-deterioration-hepatic-...
03.08.26
The study on molecular changes related to energy metabolism in Huntington’s disease subjects - looking for biomarkers
32 kB
anonymous
f09-molecular-changes-related-to-energ...
03.08.26
The autoimmune profile of Huntington`s Disease patients - a pilot study
32 kB
anonymous
f08-autoimmune-profile
03.08.26
A new biomarker in Huntington's disease
32 kB
anonymous
f15-new-biomarker
Folder contains 13 documents.
about us
|
privacy statement
|
disclaimer
|
terms of use